News
CDXS
2.650
-5.36%
-0.150
Weekly Report: what happened at CDXS last week (0415-0419)?
Weekly Report · 4d ago
Codexis to Report First Quarter 2024 Financial Results on May 2
Codexis, Inc. Will report its financial results for the first quarter of 2024 on May 2, 2024. Management will host a conference call and webcast to discuss the Company's financial results and provide a business update. Codexis is a leading enzyme engineering company.
Barchart · 04/18 15:05
Further weakness as Codexis (NASDAQ:CDXS) drops 11% this week, taking three-year losses to 88%
The share price of Codexis, Inc. Is down 88% in the last three years. The company's shareholders have lost 34% in just the last year. Codexis grew revenue at 4.4% per year, but the company is losing money in pursuit of growth. We like that insiders have been buying shares in the past 12 months. But the company's share price is down 23% in three years, and is down 14% in a month.
Simply Wall St · 04/15 11:06
Weekly Report: what happened at CDXS last week (0408-0412)?
Weekly Report · 04/15 09:18
CODEXIS APPOINTS CAROLE COBB, MBA, TO STRATEGIC ADVISORY BOARD
Reuters · 04/11 11:05
Press Release: Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board Cobb adds RNA industry operations and commercial expertise to support continued development of ECO Synthesis(TM) manufacturing platform. Ms. Cobb is the former Chief Operating Officer at GreenLight Biosciences. Codexis is a leading enzyme engineering company.
Dow Jones · 04/11 11:05
Codexis Appoints Carole Cobb, MBA, to Strategic Advisory Board
Carole Cobb, MBA, is the former Chief Operating Officer at GreenLight Biosciences. Her deep biotechnology experience includes leadership roles in fermentation-based commercial manufacturing. Ms. Cobb joins Codexis' Strategic Advisory Board. Codexis is a leading enzyme engineering company.
Barchart · 04/11 06:05
Weekly Report: what happened at CDXS last week (0401-0405)?
Weekly Report · 04/08 09:20
Weekly Report: what happened at CDXS last week (0325-0329)?
Weekly Report · 04/01 09:19
Weekly Report: what happened at CDXS last week (0318-0322)?
Weekly Report · 03/25 09:20
AQST,CDXS and STI are among after hour movers
On the Move AQST,CDXS and STI are among after hour movers. Taysha Gene Therapies (TSHA) and Canopy Growth Corporation (CGC) are among Gainers. Aquestive Therapeutics (AQST) is among the losers.
Seeking Alpha · 03/19 21:37
Weekly Report: what happened at CDXS last week (0311-0315)?
Weekly Report · 03/18 09:19
Weekly Report: what happened at CDXS last week (0304-0308)?
Weekly Report · 03/11 09:19
Weekly Report: what happened at CDXS last week (0226-0301)?
Weekly Report · 03/04 09:19
Benchmark raises Codexis to buy; cites Q4 earnings, guidance
Healthcare Benchmark raises Codexis to buy; cites Q4 earnings, guidance. The company is slated to launch its ecoRNA ligase in the first half of 2024. Benchmark set its price target for Codexis at $9. The investment firm cites the company's positive Q4 Earnings report and guidance.
Seeking Alpha · 03/01 20:37
Piper Sandler Sticks to Their Buy Rating for Codexis (CDXS)
TipRanks · 03/01 12:48
A New Cause for Concern: Codexis Adds a New Corporate Activity and Growth Risk
TipRanks · 03/01 06:00
12 Health Care Stocks Moving In Thursday's After-Market Session
Cardiff Oncology (NASDAQ:CRDF) shares moved upwards by 28.6% to $2.27 during Thursday's after-market session. The company's, Q4 earnings came out today. Burning Rock Biotech stock rose 10.84% and Kineta shares increased by 20.6%.
Benzinga · 02/29 21:31
Codexis Price Target Announced at $9.00/Share by Benchmark
Dow Jones · 02/29 15:50
Codexis Raised to Buy From Hold by Benchmark
Dow Jones · 02/29 15:50
More
Webull provides a variety of real-time CDXS stock news. You can receive the latest news about Codexis Inc through multiple platforms. This information may help you make smarter investment decisions.
About CDXS
Codexis, Inc. is an enzyme engineering company. It is leveraging its CodeEvolver technology platform to discover, develop, enhance, and commercialize novel, high performance enzymes and other classes of proteins. It utilizes its CodeEvolver technology platform to develop optimized enzymes that are used by some pharmaceutical companies to reduce their costs and improve the efficiency and productivity of their manufacturing processes for small molecule therapeutics. It is developing its Enzyme-Catalyzed Oligonucleotide Synthesis (ECO Synthesis) manufacturing platform to enable the scaled manufacture of RNA interference (RNAi) therapeutics through an enzymatic route. It also uses the CodeEvolver platform technology to develop enzymes for the synthesis of nucleic acids, such as DNA/RNA, including enzymes utilized in its ECO Synthesis manufacturing platform, where its enzymes are poised to deliver many of the same benefits it offers in pharmaceutical manufacturing.